Home › Cancer (all types) › NCT06633224
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
An Evaluation of Changes in the Relationships Between Fatigue and Molecular Mechanisms in Cancer Patients Receiving Curative-Intent Combined Chemotherapy and Radiation Therapy (CCRT)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the month except surgery or inductive Chemotherapy (CTX). * Participants receiving \>= 15 fractions. * Participants is male or female and is \>18 years of age on the day of signing the informed consent. * Ability to understand a written informed consent document. * Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment. * Willing to have medical records reviewed for clinical information. * Able to read, write and understand English or Spanish. Exclusion Criteria: * Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).
About the study
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.
What is being tested
- Blood Specimen Collection (procedure)
- Stool Specimen Collection (other)
- Quality of Life (QOL) Questionnaires (other)
Sponsor: University of California, San Francisco · Participants: 125 · Started: Dec 27, 2024
Contact the study team
- Imani Dunn · Phone: 877-827-3222
Official record on ClinicalTrials.gov — NCT06633224
Locations in the U.S.
| California | University of California, San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.